Zydus Hospira Oncology Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Zydus Hospira Oncology Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $4.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus Hospira Oncology Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $4.7M Trade | TransData Nexus

Product Portfolio — Top 5 by Export Value

Zydus Hospira Oncology Private Limited exports 5 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Gemcitabine	Oncology	$2.1M	42	4.5%	8
2	Oxaliplatin	Advanced Oncology	$850.0K	17	1.8%	9
3	Irinotecan	Oncology	$690.4K	22	1.7%	8
4	Docetaxel	Oncology	$600.0K	12	1.5%	6
5	Cytarabine	Advanced Oncology	$498.8K	11	4.6%	4

Zydus Hospira Oncology Private Limited exports 5 pharmaceutical products across 2 therapeutic categories with a total export value of $4.7M. The top category is Oncology (71.5% of portfolio), followed by Advanced Oncology (28.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Zydus Hospira Oncology Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Zydus Hospira Oncology Private Limited, incorporated on June 13, 2005, is a private limited company based in Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24230GJ2005PTC046246. Its authorized share capital is ₹65 crore, with a paid-up capital of ₹15 crore. The registered office is located at Plot No.3, Pharmez, Special Economic Zone, Sarkhej Bavla Highway, Village Matoda Tal Sanand, Gujarat 382213, India. The company's primary business activity is the manufacture of pharmaceutical and medicinal chemical products.

2Manufacturing Facilities

Zydus Hospira Oncology Private Limited operates manufacturing facilities within the Pharmez Special Economic Zone in Gujarat, India. Specific details regarding the locations, capacities, and specializations of these facilities are not publicly disclosed. However, the company's focus on oncology products suggests that these facilities are equipped to handle the production of specialized pharmaceutical formulations.

3Key Leadership

As of the latest available information, the board of directors includes Ganesh Narayan Nayak, Harish Rajendra Sadana, Nitinkumar Dalsukhray Parekh, Andrew David Chatfield, John Francis Kelly, Ranjit Menon, William Francis Barberich Jr, Swati, Pankaj Ramanbhai Patel, Sharvil Pankajbhai Patel, Pritiben Pankajbhai Patel, Vikramkumar Brijesh Shukla, Prashant Sharma, Arvind Sharma, and Sonya Kakkar. The company's leadership comprises professionals with diverse backgrounds, contributing to its strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Zydus Hospira Oncology Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Zydus Hospira Oncology Private Limited has engaged in regulatory processes with the U.S. Food and Drug Administration (FDA). The company has been audited by the FDA multiple times between 2009 and 2023 across its facilities. Notably, an FDA Form 483 was issued on June 30, 2023, indicating observations during an inspection. While specific details of the observations are not publicly available, such inspections are standard procedures to ensure compliance with FDA regulations. The company's engagement with the FDA suggests a commitment to meeting international regulatory standards.

2Emerging Markets

Zydus Hospira Oncology Private Limited's export activities, totaling $4.7 million USD across 104 shipments, indicate a presence in various international markets. The company's focus on oncology products positions it to address the growing demand for cancer treatments in emerging markets. While specific details regarding market penetration in Africa, Latin America, and Southeast Asia are not publicly disclosed, the company's export activities suggest an expanding footprint in these regions.

3Geographic Strategy

Zydus Hospira Oncology Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Zydus Hospira Oncology Private Limited's facilities have been subject to multiple FDA inspections between 2009 and 2023. The most recent inspection resulted in an FDA Form 483 issued on June 30, 2023, indicating observations during the inspection. While specific details of the observations are not publicly available, such inspections are standard procedures to ensure compliance with FDA regulations. The company's engagement with the FDA suggests a commitment to meeting international regulatory standards.

2WHO & EU GMP

Specific information regarding Zydus Hospira Oncology Private Limited's compliance with World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) standards is not publicly available. Given the company's focus on oncology products and its export activities, it is likely that the company adheres to international quality standards to meet the requirements of global markets.

3CDSCO & Indian Regulatory

Zydus Hospira Oncology Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology pharmaceutical sector, Zydus Hospira Oncology Private Limited faces competition from both domestic and international companies. While specific market share data is not publicly available, the company's export activities and focus on oncology products position it within a competitive landscape that includes established pharmaceutical manufacturers. The company's emphasis on quality and regulatory compliance is essential for maintaining a competitive edge in this specialized market segment.

2Key Differentiators

Zydus Hospira Oncology Private Limited's specialization in oncology products allows it to focus on a niche market with high demand. The company's adherence to international regulatory standards, as evidenced by its interactions with the FDA, demonstrates a commitment to quality and compliance. These factors contribute to the company's reputation and potential for growth in the oncology pharmaceutical sector.

3Strategic Position

Zydus Hospira Oncology Private Limited's strategic direction appears to be focused on the oncology segment, with a concentrated product portfolio. While this focus allows for specialization, it also exposes the company to risks associated with market fluctuations in the oncology sector. Diversifying the product portfolio and exploring new therapeutic areas could enhance the company's resilience and growth prospects in the global pharmaceutical market.

Buyer Due Diligence Brief — Evaluating Zydus Hospira Oncology Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Zydus Hospira Oncology Private Limited's export data indicates a consistent volume of shipments, reflecting reliability in its supply chain operations. The company's adherence to international regulatory standards, as evidenced by its interactions with the FDA, suggests a commitment to quality and compliance. These factors contribute to the company's reputation as a dependable supplier in the oncology pharmaceutical sector.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify adherence to World Health Organization Good Manufacturing Practice standards to ensure product quality.

EU GMP Certification: Ensure compliance with European Union Good Manufacturing Practice standards for market access in EU countries.

Frequently Asked Questions — Zydus Hospira Oncology Private Limited

How many pharmaceutical products does Zydus Hospira Oncology Private Limited export from India?

Zydus Hospira Oncology Private Limited exports 5 pharmaceutical products across 2 therapeutic categories. The top exports are Gemcitabine ($2.1M), Oxaliplatin ($850.0K), Irinotecan ($690.4K), Docetaxel ($600.0K), Cytarabine ($498.8K). Total export value is $4.7M.

What is Zydus Hospira Oncology Private Limited's total pharmaceutical export value?

Zydus Hospira Oncology Private Limited's total pharmaceutical export value is $4.7M, based on 104 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Zydus Hospira Oncology Private Limited cover?

Zydus Hospira Oncology Private Limited exports across 2 therapeutic categories. The largest are Oncology (71.5%, 3 products), Advanced Oncology (28.5%, 2 products).

Get Full Zydus Hospira Oncology Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Zydus Hospira Oncology Private Limited

Zydus Hospira Oncology Private Limited — Export Portfolio & Destination Treemap

Who is Zydus Hospira Oncology Private Limited? — Company Overview & Market Position

What Does Zydus Hospira Oncology Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Zydus Hospira Oncology Private Limited Therapeutic Categories — 2 Specializations